TRMT13
tRNA:m(4)X modification enzyme TRM13 homolog
Also known as: CCDC76, FLJ10287, FLJ11219, TRM13_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NUP7
- Gene
- TRMT13
- Ensembl
- ENSG00000122435
- Chromosome
- 1
- Canonical length
- 481 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol
OverviewNCBI Gene
Predicted to enable tRNA methyltransferase activity. Predicted to be involved in tRNA methylation. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
481 residues, UniProt reviewed canonical sequence.
>Q9NUP7|TRMT13
1 MATSATSPHA PGFPAEGRCG YYVEKKKRFC RMVVAAGKRF CGEHAGAAEE EDARKRILCP
61 LDPKHTVYED QLAKHLKKCN SREKPKPDFY IQDINAGLRD ETEIPEQLVP ISSLSEEQLE
121 KLIKKLRKAS EGLNSTLKDH IMSHPALHDA LNDPKNGDSA TKHLKQQASI LGNIENLKLL
181 GPRRCFVEFG AGKGKLSHWV DIALKDAEKV HFILVEKVTT RFKVDGKHRK KNSVFERLQI
241 DIQHLCLNKI PVLREEKLPV VGIGKHLCGM ATDLALRCLV ETYAASFEER NEEPLAKRIK
301 NDKTEKEIYT LAKEGNEKNV PEKWNPVAGI VIALCCHHRC DWRHYVGKEY FRALGLGAVE
361 FHYFQRMSSW ATCGMRKTSL ETSNSTTKRQ DNQNDDSEEH DDGGYRITDD GADCLPGLLS
421 VEEKKKIGHL CKLLIDQGRI QYLQQKGFSP ALQYYTDPLV SLENVLLTAL PNHSSSPETT
481 ALocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRMT13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 20 nTPM
Expression across tissuesHPA
Tissue
- retina: 20 nTPM
- lymph node: 17 nTPM
- skin: 14 nTPM
- tonsil: 14 nTPM
- breast: 14 nTPM
- spleen: 13 nTPM
Single-cell type
- cardiomyocytes: 134 nCPM
- oligodendrocytes: 97 nCPM
- myonuclei: 87 nCPM
- oocytes: 69 nCPM
- distal convoluted tubule cells: 67 nCPM
- adrenal medulla cells: 64 nCPM
Immune cell
- memory B-cell: 20 nTPM
- naive B-cell: 19 nTPM
- naive CD4 T-cell: 17 nTPM
- naive CD8 T-cell: 14 nTPM
- MAIT T-cell: 13 nTPM
- plasmacytoid DC: 13 nTPM
Brain region
- white matter: 29 nTPM
- cerebellum: 19 nTPM
- basal ganglia: 19 nTPM
- hypothalamus: 19 nTPM
- midbrain: 18 nTPM
- medulla oblongata: 17 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.93
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.41
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Protein domainsUniProt · Pfam · InterPro
- TRM13/UPF0224 family, U11-48K-like CHHC zinc finger domain
- U11-48K-like CHHC zinc finger
- Methyltransferase TRM13
- Zinc finger, CCCH-type, TRM13
- tRNA:m(4)X modification enzyme Trm13
- Methyltransferase TRM13
- CCCH zinc finger in TRM13 protein
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRMT13 as an antibody target. Whether an autoantibody or antibody against TRMT13 could matter depends on whether native TRMT13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRMT13 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TRMT13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...